RenovoRx, Inc. Common Stock (RNXT) is a publicly traded Healthcare sector company. As of May 19, 2026, RNXT trades at $0.80 with a market cap of $36.98M and a P/E ratio of -2.38. RNXT moved -0.26% today. Year to date, RNXT is -6.23%; over the trailing twelve months it is -33.63%. Its 52-week range spans $0.70 to $1.69. Analyst consensus is strong buy with an average price target of $6.88. Rallies surfaces RNXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RenovoRx Highlights $563K Q1 RenovoCath Sales, Phase III Enrollment Closure: RenovoRx will present at the AGP Virtual Healthcare Company Showcase on May 20, with CEO Shaun Bagai and CFO Mark Voll highlighting record first-quarter 2026 RenovoCath revenue of $563,000 and accelerating adoption at high-volume cancer centers. The company expects to complete Phase III TIGeR-PaC trial enrollment by early June and deliver final data in mid to late 2027.
| Metric | Value |
|---|---|
| Price | $0.80 |
| Market Cap | $36.98M |
| P/E Ratio | -2.38 |
| EPS | $-0.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.69 |
| 52-Week Low | $0.70 |
| Volume | 242.41K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.58M |
| Net Income | $-12.27M |
| Gross Margin | 74.04% |
4 analysts cover RNXT: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.88.